glp 1 weight regain A Comprehensive Review on Gain following Discontinuation of Glucagon‐Like Peptide‐1 Receptor Agonists for Obesity - Abdullah bin Ahmed - 2024 - Journal of Obesity The Data Are Clear: Patients

Its unique dual action on GLP-1 and GIP receptors has yielded remarkable clinical outcomes, as evidenced by multiple large-scale, peer-reviewed clinical trials

8 The occurrence of ARDS in intensive care units (ICUs) in mainland China is low, but the high mortality rate and withdrawal rate of life-saving treatment in patients with moderate-to-severe ARDS are concerning

2016, Neumann et al

[DOI] [PMC free article] [PubMed] [Google Scholar] 8.Bruls YM, de Ligt M, Lindeboom L, Phielix E, Havekes B, Schaart G, et al

Neuroprotection and Repair Alzheimers and dementia research: Dihexa was developed as a potential therapy for neurodegenerative diseases, aiming to restore connectivity lost in conditions like Alzheimers

The chip was tested in modelling diabetic nephropathy and a glucose-induced damage was revealed compared to a control group ( Figure 4I )